Kirkuk Journal of Medical Sciences

PERSPECTIVE, OPINION, AND COMMENTARY

Drug Review and Development: Innovations, Challenges, and Ethical Considerations

Reema Hisham Shakhatreh [1,*] and Hisham Jadallah Shakhatreh [2]

[1]*Faculty of Pharmacy, Jadara University, Jordan*
[1]*Faculty of Law, Jadara University, Jordan*

[*]*Corresponding author email: r.shakhatreh19@gmail.com*

Received: 01 March 2024
Accepted: 01 June 2024
First published online: 01 April 2025

*DOI:*10.32894/kjms.2024.147350.1100.

Drug development process has been improved significantly last decades but it is still expensive, because of time consuming and ethical issues. While regulatory bodies are trying to balance safety, efficacy, and innovation, new challenges like antimicrobial resistance, precision medicine, and artificial intelligence in drug discovery require rethinking some traditional approaches.

In this commentary, We explore the ongoing complexities of drug review and development and highlight the urgent need for regulatory reforms, equitable access, and ethical considerations in the face of emerging technologies

The pharmaceutical industry has made tremendous strides, but the drug development value chain is recognized as long and costly. A study by Dimasi et al. [1] estimates that developing a new drug costs, on average, $1.5 billion and takes over a decade. These challenges include accessibility, affordability, and sustainability. Additionally, while regulatory standards are essential for ensuring patient safety, they can also delay drug approvals, particularly for life-threatening diseases [2].

Scientific innovations redefine medicine and so regulatory frameworks have to evolve to be safe and not to stifle innovation. Ethical dilemmas, conventional drug review processes [3], and big data analytics and personalized medicine challenge and are enabled by artificial intelligence (AI). This commentary explores the critical aspects of drug development, including future directions for reform and regulatory constraints.

Regulatory Challenges and Bottlenecks

Although research methodologies are in advance, both the FDA and EMA require numerous clinical trials to certify safety and efficacy. The traditional phased clinical trial model faces criticism for being slow and financially burdensome [4]. Moreover, there is still no resolution to the ethical dilemma posed by placebo-controlled trials in critical illnesses.

New approaches like adaptive clinical trials and real world evidence (RWE) are very promising. Adaptive trial designs, for example, are designed to change based on interim data, thus reducing time and cost [5]. As for the latter, RWE from electronic health records can be used to speed up drug approvals without compromising safety standards [6]. However, regulatory bodies must have clear and solid guidelines for these approaches as well.

The Role of AI in Drug Development

AI driven drug discovery is changing pharmaceutical research and development by decreasing the time of drug discovery and optimization [7]. Artificial machine learning models are capable of predicting drug target interactions, finding new indications for existing drugs, and designing better clinical trials. However, there are concerns about the bias, privacy, and robustness of the data and algorithms as well as the standards for validation causability [8].

Although the application of AI in drug discovery has the potential to revolutionize the drug development process, its integration with the regulatory review process is still at the beginner's level. Agencies must issue AI-specific guidelines to guarantee the transparency, reproducibility, and compliance of AI-assisted drug evaluations [9].

Lack of proper oversight may result in the perpetuation of biases and the ignoring of safety issues.

Equitable Access and Global Disparities

A major issue in drug development is the unequal access to lifesaving drugs. Although, new therapies are being offered to the high income countries first, the lower income regions are affected by the problems of cost and supply chain break down [10].

Patent laws and monopolistic practice contribute to the existing inequalities by restricting generic competition and high pricing drugs [11].

Intiative such as the WHO's Essential Medicines List is trying to address this gap globally but policy measures are required to make it sustainable so that access to treatment is not at the cost of innovation.

Ethical Considerations in Drug Development

Ethical issues are raised at every stage of the drug development process from the design of clinical trials to post marketing surveillance. This paper highlights the problem of vulnerable populations being exploited in clinical trials and the need for better ethical supervision [12]. The growing role of pharmaceutical companies in regulatory decisions also raises issues of conflict of interest and potential industry bias [13].

New ethical issues arise in personalized medicine based on genetic data, with potential unfairness in access [14]. With precision medicines becoming more common, regulatory authorities must guarantee the implementation of ethical standards to ensure that patient autonomy and non discrimination are respected.

Conclusion

The drug development is at a crossroads; while technological advancements present unprecedented opportunities, systemic challenges persist. Regulatory agencies must move from antiquated risk-based to modern science-based paradigms and must continue to safeguard patient safety. It is possible to enhance the efficiency of the drug review processes by integrating AI, adaptive trial designs, and real world evidence without compromising ethical integrity.

In addition, an integrated global effort to reform patent laws and encourage cost effective drug production is required to address affordability and equitable access. Ethical considerations must be central to all reforms and include transparency, fairness, and public trust.

As we move forward, a multidisciplinary approach that combines scientific innovation with ethical vigilance will be key to revolutionizing drug development for the betterment of global health.

ETHICAL DECLARATIONS

- **Acknowledgements**

  None.

- **Ethics Approval and Consent to Participate**

  Not required for Perspective, opinion, and commentary article.

- **Consent for Publication**

  Not applicable.

- **Availability of Data and Material**

  No individual personal data is included.

- **Competing Interests**

  The author declares that there is no conflict of interest.

- **Funding**

  Self funded.

- **Authors' Contributions**

  All authors are responsible for the literature review and writing the manuscript. The author read and approved the final version of the manuscript.

REFERENCES

[1] DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of health economics 2016;47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012.

[2] Vukicevic S. Current challenges and hurdles in new drug development. Clinical Therapeutics 2016;38(10):e3. https://doi.org/10.1016/j.clinthera.2016.07.019.

[3] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine 2019;25(1):44–56. https://doi.org/10.1038/s41591-018-0300-7.

[4] Barlas S. The clinical trial model is up for review: time, expense, and quality of results are at issue, as is the relationship to drug pricing. Pharmacy and Therapeutics 2014;39(10):691.

[5] Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. CRC press; 2010.

[6] Schad F, Thronicke A. Real-world evidence—current developments and perspectives. International Journal of Environmental Research and Public Health 2022;19(16):10159. https://doi.org/10.3390/ijerph191610159.

[7] Zhavoronkov A, Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. ACS Publications; 2018. https://doi.org/10.1021/acs.molpharmaceut.8b00930.

[8] Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery 2019;9(4):e1312. https://doi.org/10.1002/widm.1312.

[9] Oualikene-Gonin W, Jaulent MC, Thierry JP, Oliveira-Martins S, Belgodère L, Maison P, et al. Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities. Frontiers in pharmacology 2024;15:1437167. https://doi.org/10.3389/fphar.2024.1437167.

[10] Reich MR. The global drug gap. Science 2000;287(5460):1979–1981. https://doi.org/10.1126/SCIENCE.287.5460.1979.

[11] Gurgula O. Strategic patenting by pharmaceutical companies–should competition law intervene? IIC-International Review of Intellectual Property and Competition Law 2020;51(9):1062–1085. https://doi.org/10.1007/s40319-020-00985-0.

[12] Iyalomhe G, Imomoh P. Ethics of clinical trials. Nigerian Journal of Medicine 2007;16(4):301–306. https://doi.org/10.4314/NJM.V16I4.37326.

[13] Abraham J. Sociology of pharmaceuticals development and regulation: a realist empirical research programme. Sociology of health & illness 2008;30(6):869–885. https://doi.org/10.1111/j.1467-9566.2008.01101.x.

[14] Francisco KKY, Apuhin AEC, Tan MJT, Byers MC, Maravilla NMAT, Karim HA, et al. Can Personalized Medicine Coexist with Health Equity? Examining the Cost Barrier and Ethical Implications. arXiv preprint arXiv:241102307 2024;https://doi.org/10.48550/arXiv.2411.02307.